Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303303 · ClinicalTrials.gov registry record · Phase 4
The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT00303303: Clinical Trial Phase 4 study, sponsored by Wake Forest University Health Sciences.
NCT00303303 is a Phase 4 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 13 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303303, a Phase 4 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
Most patients bitten by copperhead snakes do not currently receive antivenom. Some snakebite victims have long term problems with the function of the limb that was bitten. This study will determine whether early administration of antivenom to patients with mild to moderate copperhead snakebites reduces long-term complications.
Primary Outcome
The range of possible scores is 0 - 100, and a lower score denotes less disability.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)
- BIOLOGICAL Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2005-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
Why NCT00303303 stopped before completion
NCT00303303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00303303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00303303 about?
NCT00303303 is a clinical study titled "The Efficacy of Crotaline Fab Antivenom for Copperhead Snake Envenomations". Most patients bitten by copperhead snakes do not currently receive antivenom. Some snakebite victims have long term problems with the function of the limb that was bitten. This study will determine whether early administration of antivenom to patients with mild to moderate copperhead snakebites redu...
What is the current status of trial NCT00303303?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2005-04. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00303303?
The interventions under investigation include: Placebo (BIOLOGICAL), Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy) (BIOLOGICAL), Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00303303?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00303303's enrollment target sits among peer trials
13 1910th of 2000 higher than 88 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia